|
|
|
|
|
Highlights from the 2023 ASCO Genitourinary Cancers Symposium
|
|
|
|
|
|
|
| Ending Cancer as We Know It: Predicting Future Cancer Progress |
| Norman E. Sharpless, MD
|
| The 2023 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium was host to a Keynote Session delivered by Dr. Norman Sharpless, former director of the National Cancer Institute from 2017 to 2022.
|
|
|
|
|
|
| Rapid Abstract Session: Urothelial Carcinoma
|
|
| Complimentary Genomic, Pathologic, and Artificial Intelligence Analysis on Low-Grade Noninvasive Bladder Cancer to Predict Downstream Recurrence
|
| Kyle M. Rose, MD
|
| Kyle Rose discussed prediction of downstream recurrence using complimentary genomic, pathologic, and artificial intelligence analysis for low-grade noninvasive bladder cancer. Using a multi-disciplinary approach, this study identified key signatures in recurrent low-grade noninvasive bladder cancer.
|
|
|
|
|
|
| Randomised Phase II Trial of Adaptive Image Guided Radiotherapy in Muscle Invasive Bladder Cancer: Late Toxicity and Cancer Outcomes
|
| Robert A Huddart, MBBS, FRCR, MRCP, Ph.D.
|
| Robert Huddart presented the results of RAIDER CRUK/14/016, a randomized phase II trial of adaptive image-guided standard or dose escalated tumor boost radiotherapy in the treatment of transitional cell carcinoma of the bladder.
|
|
|
|
|
|
| Co-Primary Endpoint Analysis of HCRN GU 16-257: Phase 2 Trial of Gemcitabine, Cisplatin, plus Nivolumab with Selective Bladder Sparing in Patients with Muscle-Invasive Bladder Cancer (MIBC)
|
| Matt D. Galsky, MD, FASCO |
| Matt Galsky presented the co-primary endpoint analysis of HCRN GU 16-256, a phase II trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer.
|
|
|
|
|
|
|
|
|
|
|
| HCRN GU14-188: Phase Ib/II Study of Neoadjuvant Pembrolizumab and Chemotherapy for T2-4aN0M0 Urothelial Cancer |
| Jason Brown, MD, Ph.D. |
| Jason Brown presented the results of HCRN GU14-188, a Phase Ib/II study of neoadjuvant pembrolizumab and chemotherapy for T2-4aN0M0 urothelial cancer. |
|
|
|
|
|
| Benefit of Whole-Pelvis Radiation for Patients with Muscle-Invasive Bladder Cancer: An Inverse Probability Treatment-Weighted Analysis |
| Ronald Kool, MD
|
| Ronald Kool presented an inverse probability treatment-weighted analysis of the benefit for whole-pelvis versus bladder only radiation for patients with muscle-invasive bladder cancer.
|
|
|
|
|
|
| Primary Analysis of TROPHY-U-01 Cohort 2, a Phase 2 Study of Sacituzumab Govitecan in Platinum-Ineligible Patients with Metastatic Urothelial Cancer That Progressed after Prior Checkpoint Inhibitor Therapy
|
| Daniel P. Petrylak, MD
|
| Daniel Petrylak presented the results of the TROPHY-U-01 Cohort 2, a phase II study of Sacituzumab Govitecan in platinum-ineligible patients with metastatic urothelial carcinoma who had progressed after prior checkpoint inhibitor therapy.
|
|
|
|
|
|
| Poster Session: Urothelial Carcinoma |
| Phase 2 Study of the Efficacy and Safety of Erdafitinib in Patients with Bacillus Calmette-Guérin-Unresponsive, High-Risk Non–Muscle-Invasive Bladder Cancer with FGFR3/2 Alterations in THOR-2
|
| James W.F. Catto, PhD, FRCS
|
| James Catto highlighted an interim analysis of cohort 2 of the THOR-2 trial, assessing the efficacy and safety of erdafitinib in patients with bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (HR-NMIBC) with FGFR3/2 alterations.
|
|
|
|
|
|
|
|
|
|
|
| The Impact of Blue Light Cystoscopy Use Among Patients with Non-Muscle Invasive Bladder Cancer in an Equal Access Setting
|
| Sanjay Das, MD |
| Sanjay Das presented an abstract evaluating the impact of Blue Light Cystoscopy (BLC) use among patients with NMIBC in an equal access setting, specifically the Veterans Affairs (VA) system. |
|
|
|
|
|
| Quality of Life in QUILT 3.032 Study: Patients with BCG-Unresponsive NMIBC Receiving IL-15RαFc Superagonist N-803 plus BCG |
| Karim Chamie, MD
|
| Karim Chamie discussed quality of life in the QUILT 3.032 study, specifically patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15RαFc superagonist N-803 plus BCG.
|
|
|
|
|
|
| Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Follow-up from the JAVELIN Bladder 100 Trial in Subgroups Defined by 1L Chemotherapy Regimen and Analysis of Overall Survival from Start of 1L Chemotherapy |
| Srikala S. Sridhar, MD, MSc, FRCPC
|
| Kala Sridhar presented long-term follow-up from the JAVELIN Bladder 100 clinical trial in subgroups defined by first line (1L) chemotherapy regimen and an overall survival (OS) analysis from the start of 1L chemotherapy. |
|
|
|
|
|
| A Phase II Clinical Study of Intravesical Photo Dynamic Therapy in Patients with BCG-Unresponsive NMIBC (Interim Analysis)
|
| Girish S. Kulkarni, MD, PhD |
| Girish Kulkarni highlighted the interim results assessing of intravesical photo dynamic therapy in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). |
|
|
|
|
|
| Primary Analysis of TROPHY-U-01 Cohort 3, a Phase 2 Study of Sacituzumab Govitecan in Combination with Pembrolizumab in Patients with Metastatic Urothelial Cancer That Progressed After Platinum-Based Therapy
|
| Petros Grivas, MD, Ph.D |
| Petros Grivas reported updated results of the single arm TROPHY-U-01 Cohort 3. The authors demonstrate that the combination of SG and pembrolizumab resulted in high ORR and clinical benefit rate, as well as a manageable safety profile, as second line treatment of patients with metastatic UC following platinum-based chemotherapy exposure and without prior immune checkpoint inhibitor treatment. |
|
|
|
|
|
| Comparative Real-World Survival Outcomes of Muscle-Invasive Bladder Cancer Treated with Bladder-Only vs. Whole-Pelvis Concurrent Chemoradiation |
| Carlos Riveros, MD |
| Carlos Riveros discussed comparative real-world survival outcomes of muscle-invasive bladder cancer treated with bladder-only versus whole-pelvis concurrent chemoradiation.
|
|
|
|
|
|
| Intravesical Gemcitabine and Docetaxel in the Treatment of BCG-Naïve Non–Muscle Invasive Urothelial Carcinoma of the Bladder: Updates from a Phase 2 Trial
|
| Max R. Kates, MD
|
| Max Kates discussed updates from a phase 2 trial assessing intravesical gemcitabine and docetaxel in the treatment of BCG-naïve non–muscle invasive bladder cancer (NMIBC).
|
|
|
|
|
|
 |
